- Home
- PPBI vs XENE Comparison
PPBI vs XENE Comparison
Compare PPBI & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBI
- XENE
- Stock Information
- Founded
- PPBI 1983
- XENE 1996
- Country
- PPBI United States
- XENE Canada
- Employees
- PPBI N/A
- XENE N/A
- Industry
- PPBI Major Banks
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- PPBI Finance
- XENE Health Care
- Exchange
- PPBI Nasdaq
- XENE Nasdaq
- Market Cap
- PPBI 2.7B
- XENE 3.3B
- IPO Year
- PPBI 1997
- XENE 2014
- Fundamental
- Price
- PPBI $24.77
- XENE $38.37
- Analyst Decision
- PPBI Buy
- XENE Strong Buy
- Analyst Count
- PPBI 6
- XENE 9
- Target Price
- PPBI $26.50
- XENE $56.67
- AVG Volume (30 Days)
- PPBI 463.5K
- XENE 350.2K
- Earning Date
- PPBI 01-27-2025
- XENE 11-12-2024
- Dividend Yield
- PPBI 5.28%
- XENE N/A
- EPS Growth
- PPBI N/A
- XENE N/A
- EPS
- PPBI N/A
- XENE N/A
- Revenue
- PPBI $379,785,000.00
- XENE N/A
- Revenue This Year
- PPBI N/A
- XENE N/A
- Revenue Next Year
- PPBI N/A
- XENE $1,599.99
- P/E Ratio
- PPBI N/A
- XENE N/A
- Revenue Growth
- PPBI N/A
- XENE N/A
- 52 Week Low
- PPBI $20.52
- XENE $35.53
- 52 Week High
- PPBI $30.28
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- PPBI 43.91
- XENE 37.35
- Support Level
- PPBI $26.56
- XENE $38.95
- Resistance Level
- PPBI $27.63
- XENE $41.62
- Average True Range (ATR)
- PPBI 0.77
- XENE 1.64
- MACD
- PPBI -0.21
- XENE -0.35
- Stochastic Oscillator
- PPBI 9.12
- XENE 7.34
About PPBI Pacific Premier Bancorp Inc
Pacific Premier Bancorp Inc through its subsidiaries, provides banking products and services. It offers cash management, electronic banking services, credit facilities, and retirement accounts, among others.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.